Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RIGLthis companyRigel Pharmaceuticals, Inc.	$41.32	2.1×	1.97×	2.62×	5.95×	-171.8%	93.3%	42.6%	124.7%	93.8%	28.2%	9.8%	0.14×	0.1×	17.14×	2.42×	0.0%	4	4.57	4	A
ALXOALX Oncology Holdings Inc.	$1.22	-0.59×	2.33×	0×	-0.5×	-90.6%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-2.66	2	C
CCCCC4 Therapeutics, Inc.	$3.12	-1.5×	0.62×	4.4×	-1.4×	-187.2%	77.8%	-290.7%	-292.1%	-40.9%	-31.4%	-62.7%	0.23×	0.14×	0×	7.81×	0.0%	3	-1.03	2	C
CGEMCullinan Therapeutics, Inc.	$11.61	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
CRDFCardiff Oncology, Inc.	$0.84	-4.07×	4.14×	316.73×	-3.81×	-96.7%	100.0%	-8256.3%	-7732.0%	-101.0%	-105.9%	-20.2%	0.02×	0.37×	0×	3.67×	0.0%	2	-16.02	2	C
CRISCuris, Inc.	$0.74	-1.7×	2.38×	1.38×	-1.83×	-1429.1%	99.5%	-348.4%	-80.3%	-138.8%	-464.7%	-209.4%	0.3×	0.66×	-15.06×	0.49×	0.0%	0	-98.45	1	C-
Peer median	—	-1.7×	2.33×	1.38×	-1.83×	-96.7%	77.8%	-290.7%	-80.3%	-101.0%	-105.9%	-62.7%	0.2×	0.37×	0×	3.67×	0.0%	2	-2.66	2	—